Lexology November 8, 2024
Morgan Lewis & Bockius LLP

The reelection of former President Donald Trump, coupled with Republicans gaining the Senate majority and poised to gain the House majority, has prompted many in the life sciences industry to question how this political shift may impact the regulation of drugs, devices, and other life sciences products by FDA and related regulators. While the now President Elect has not yet articulated specific policy priorities with respect to the life sciences industry, what is clear is that the sector is positioned to see significant changes. We describe below key areas to watch as the new Trump-Vance administration takes shape.

NEW AGENCY HEADS AND PRIORITIES

As is generally the case, the President Elect is expected to make changes at the top levels...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
Congressional spending plan: What’s in it for healthcare, and what isn’t
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
Telehealth groups call for urgent action as Medicare flexibility deadline looms
Another House bill aims to protect against hospital cyberattacks
A health care earthquake in Congress

Share This Article